Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RBC BioscienceROCO:6848 +4.86%76 Quick Ratio is 0.76 as of Dec. 2025, which is 21% below its 10-year median of 0.96. GuruFocus rates ROCO:6848 with a GF Score™ of 76/100 and a GF Value™ of NT$19.91 (Fairly Valued). The stock has 7 warning signs investors should review. Among 1,411 Biotechnology companies, RBC Bioscience ranks worse than 85.61% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. RBC Bioscience's quick ratio for the quarter that ended in Dec. 2025 was 0.76.
RBC Bioscience has a quick ratio of 0.76. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for RBC Bioscience's Quick Ratio or its related term are showing as below:
ROCO:6848'
s Quick Ratio Range Over the Past 10 Years
Min: 0.76 Med: 0.96 Max: 2.06
Current: 0.76
During the past 9 years, RBC Bioscience's highest Quick Ratio was 2.06. The lowest was 0.76. And the median was 0.96.
ROCO:6848's Quick Ratio is ranked worse than 85.61% of 1411
companies
in the Biotechnology industry
Industry Median: 3.6
vs ROCO:6848: 0.76
RBC Bioscience (ROCO:6848) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
RBC Bioscience Quick Ratio Related Terms
RBC Bioscience Quick Ratio Historical Data
* Premium members only.
The historical data trend for RBC Bioscience's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6848 vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, RBC Bioscience's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RBC Bioscience Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RBC Bioscience's Quick Ratio distribution charts can be found below:
* The bar in red indicates where RBC Bioscience's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
RBC Bioscience's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RBC Bioscience (ROCO:6848) has a Quick Ratio of 0.76 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on RBC Bioscience and its competitors. This is 21% below median its historical median of 0.96. Over the past decade, RBC Bioscience's Quick Ratio has ranged from 0.76 to 2.06. According to the industry distribution chart, RBC Bioscience ranks #1208 out of 1411 companies in the Biotechnology industry, placing it in the top 85.6%.
Is RBC Bioscience's Quick Ratio too high?
RBC Bioscience's current Quick Ratio of 0.76 is 21% below median its 10-year median of 0.96. Over the past 10 years, this metric has ranged from a low of 0.76 to a high of 2.06. The Biotechnology industry median Quick Ratio is 3.60. RBC Bioscience's value of 0.76 is 78.9% below this industry median. Based on the distribution chart, RBC Bioscience ranks #1208 out of 1411 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, RBC Bioscience has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does RBC Bioscience's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RBC Bioscience ranks #1208 out of 1411 companies for Quick Ratio. This places RBC Bioscience in the lower half of its industry. The industry median Quick Ratio is 3.60. RBC Bioscience's value of 0.76 is 78.9% below this benchmark. Historically, RBC Bioscience's own Quick Ratio has ranged from 0.76 to 2.06 over the past decade. While the company's 10-year median is 0.96 vs. the industry median of 3.60, RBC Bioscience has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RBC Bioscience's current Quick Ratio of 0.76 is 78.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on RBC Bioscience and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RBC Bioscience's current Quick Ratio is 0.76, which is 21% below median its own 10-year median of 0.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RBC Bioscience stock overvalued right now?
Based on GuruFocus' analysis, RBC Bioscience (ROCO:6848) is currently considered Fairly Valued. The stock's GF Value™ is NT$19.91, compared to a current price of NT$20.50 — trading 3% above its estimated fair value. The current Quick Ratio is 0.76, which is 21% below median its 10-year median of 0.96 and 78.9% below the Biotechnology industry median of 3.60. RBC Bioscience's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For RBC Bioscience (ROCO:6848), the current Quick Ratio is 0.76 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RBC Bioscience (ROCO:6848) Overvalued in 2026?
Based on GuruFocus' analysis, RBC Bioscience stock appears to be overvalued.
The current stock price of NT$20.50 is trading 3% above its estimated GF Value™ of NT$19.91.
GuruFocus considers RBC Bioscience to be Fairly Valued.
Key valuation signals for ROCO:6848:
Quick Ratio: 0.76 (21% below median its 10-year median of 0.96)
GF Value™: NT$19.91 vs. price of NT$20.50 (3% above fair value)
Industry Position: 78.9% below the Biotechnology median (#1208 of 1411)
No single metric tells the full story. See the ROCO:6848 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RBC Bioscience Corp is a bio-sciences company. Its products include the manufacture and sale of molecular biological medical diagnosis and research reagents, gene extraction automatic testing instruments, and gene extraction reagent tissues.
76GF Score
Get the complete analysis for ROCO:6848
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6848 has been successfully added to your 
